Search Results

Your search for Matthew Smith, MD, PhD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / Tuesday, August 29, 2017 9:29 AM

FDA Approves Fulvestrant as Monotherapy for Expanded Use in Breast Cancer

On August 28, the U.S. Food and Drug Administration (FDA) approved fulvestrant (Faslodex) at 500 mg as monotherapy for expanded use in women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who have gone through menopause...

breast cancer

By The ASCO Post Staff / Monday, July 31, 2017 9:58 AM

Fulvestrant Receives EC Approval as First-Line Therapy for Advanced Breast Cancer

On July 26, the European Commission (EC) approved fulvestrant (Falsodex) for the treatment of estrogen receptor–positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The EC approval is based on pivotal data from the...

Apr

Today In Oncology

Search Results

Your search for Matthew Smith, MD, PhD matches 2 pages

FDA Approves Fulvestrant as Monotherapy for Expanded Use in Breast Cancer

Fulvestrant Receives EC Approval as First-Line Therapy for Advanced Breast Cancer

Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC

An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma